Stericycle’s self-help measures and significant exposure to the growing United States medical waste market

Business Strategy and Outlook

Since its founding in 1989, Stericycle has been extremely acquisitive, having acquired over 500 companies. On the surface, this acquisitive strategy led to a lengthy period of impressive growth and the firm built unmatched scale. However, acquisitions began to stray from Stericycle’s core competencies and poor integration efforts caused inefficiencies to build. After decades of strong growth and profitability, Stericycle’s financial performance began to deteriorate in 2017. However, with a refreshed management team, led by CEO Cindy Miller, it is now seen Stericycle has turned the corner. With Miller at the helm, Stericycle has divested low-margin, noncore businesses, most notably, environmental solutions. The enterprise resource planning implementation project continues, and it is likely to be completed within the next couple of years. A common ERP system will streamline Stericycle’s operations and improve the firm’s financial planning and analysis. Finally, Miller has implemented much needed oversight and standardization, for example, customer contracts are now reviewed by a deal review committee.

Management’s turnaround efforts are taking hold. Despite the global pandemic, Stericycle’s regulated waste and compliance services business reported 2% organic growth in 2020 (after flat organic growth in 2019 and a 2% organic decline in both 2018 and 2017), and consolidated gross margin improved 60 basis points year over year after six consecutive years of gross margin contraction. In 2021, RWCS registered nearly 6% organic revenue growth, and the secure information destruction services business reported 5% organic growth.

Stericycle’s self-help measures and significant exposure to the growing United States medical waste market should result in solid top-line growth and margin expansion over the next five years. It is foreseen, Stericycle’s revenue to grow at about a 4% five-year compound annual rate and adjusted EBITDA margin to expand to around 23.5% by 2025-26 from (17.5% to 18.5% during 2019-21). Most importantly, it is alleged for return on new invested capital will rebound to the low double digits by 2024.

Financial Strength

Stericycle’s debt balance increased by over $1.5 billion in 2015 a result of the Shred-It acquisition. As the company’s financial performance deteriorated in subsequent years, the firm’s net debt/EBITDA ratio swelled to approximately 4.5. However, the current management team is committed to rightsizing the balance sheet, and the firm’s leverage ratios have already become more palatable (net debt/adjusted EBITDA was about 3.4 as of December 2021). Stericycle ended its first-quarter 2022 with $1.65 billion of net debt. The firm’s outstanding balance on its credit facility and term loan (approximately $540 million) is due in 2026, $600 million of 5.375% senior notes is due in 2024, and $500 million of 3.875% senior notes is due in 2029. Over the next five years, it is projected Stericycle will generate approximately $1.7 billion of free cash, so about the firm’s ability to service its outstanding debt is not a concern, and it is held, management’s goal of reducing its net debt/adjusted EBITDA ratio below 3 is achievable. Stericycle has plenty of liquidity with $60 million of cash on the balance sheet and over $790 million available on its $1.2 billion credit facility.

Bulls Say’s

Stericycle’s turnaround efforts will prove successful, materially improving the firm’s profitability and free cash flow.
Medical waste volume should grow faster than U.S. GDP due to an aging population that requires more medical procedures. Stericycle’s leading position in an expanding market should improve the firm’s financial prospects.
Stericycle is past the apex of pricing pressure related to private practice consolidation and a customer class action lawsuit. Going forward, the firm should realize annual price increases above inflation.

Company Profile

Stericycle is the largest provider of medical waste disposal and data destruction (primarily paper shredding) services in the United States. Its next closest national competitor in the medical waste disposal space is Sharps Compliance, which generated $76 million of sales in fiscal 2021 (about 4% of Stericycle’s global regulated waste and compliance revenue). Stericycle’s data destruction business (Shred-It) is about twice the size of its closest competitor (Iron Mountain’s information destruction segment). Stericycle has a global presence, with about 20% of its revenue earned outside North America.

(Source: MorningStar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.